The opportunity.
With financial support from the ongoing capital injection, SeqCure estimates that clinical Proof-of-Concept can be reached within 4 years. Furthermore, regulatory pathways exist to support a fast- track clinical development program and approval process.
Based on data from clinical trials using autologous (derived from the same individual) tumor- infiltrating lymphocytes and the unprecedented tumor specificity of SeqCureNEO, the product can be expected to be well tolerated compared to many other types of cancer treatment, including cell therapies involving genetic engineering.
Key competitive features of SeqCureNEO include:
Highly individualized. The cell product is tailor-made from the mutation profile of each individual patient tumor.
Unprecedented level of control over tumor specificity, resulting in a cell product with high purity.The high purity enables delivery of the required dose to achieve a clinical response.
Whole blood (and not tumor tissue) is used as a source for the cell product, eliminating the need for additional surgical procedures.
SeqCureNEO is nonengineered and targets multiple neoantigens, ensuring high safety in combination with a much broader tumor reactivity compared to other cell immunotherapy products.